WO2004007521A3 - Bile acid derivatives as agonists of the farnesoid x receptor - Google Patents
Bile acid derivatives as agonists of the farnesoid x receptor Download PDFInfo
- Publication number
- WO2004007521A3 WO2004007521A3 PCT/EP2003/007512 EP0307512W WO2004007521A3 WO 2004007521 A3 WO2004007521 A3 WO 2004007521A3 EP 0307512 W EP0307512 W EP 0307512W WO 2004007521 A3 WO2004007521 A3 WO 2004007521A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- agonists
- farnesoid
- receptor
- acid derivatives
- bile acid
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
- C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Obesity (AREA)
- Medicinal Chemistry (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Steroid Compounds (AREA)
Abstract
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2003250935A AU2003250935A1 (en) | 2002-07-12 | 2003-07-11 | Bile acid derivatives as agonists of the farnesoid x receptor |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IT2002MI001532A ITMI20021532A1 (en) | 2002-07-12 | 2002-07-12 | CHEMICAL COMPOUNDS |
ITMI2002A001532 | 2002-07-12 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2004007521A2 WO2004007521A2 (en) | 2004-01-22 |
WO2004007521A3 true WO2004007521A3 (en) | 2004-04-01 |
Family
ID=30012506
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2003/007512 WO2004007521A2 (en) | 2002-07-12 | 2003-07-11 | Bile acid derivatives as agonists of the farnesoid x receptor |
Country Status (3)
Country | Link |
---|---|
AU (1) | AU2003250935A1 (en) |
IT (1) | ITMI20021532A1 (en) |
WO (1) | WO2004007521A2 (en) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2248581T3 (en) | 2001-03-12 | 2006-03-16 | Intercept Pharmaceuticals, Inc. | STEROIDS AS FXR AGONISTS. |
EP1568706A1 (en) | 2004-02-26 | 2005-08-31 | Intercept Pharmaceuticals, Inc. | Novel steroid agonist for FXR |
PT1734970E (en) | 2004-03-12 | 2015-03-11 | Intercept Pharmaceuticals Inc | Treatment of fibrosis using fxr ligands |
US10987362B2 (en) | 2004-03-12 | 2021-04-27 | Intercept Pharmaceuticals, Inc. | Treatment of fibrosis using FXR ligands |
US7618956B2 (en) | 2005-05-31 | 2009-11-17 | The Gillette Company | Reduction of hair growth |
CA2676417C (en) * | 2007-01-19 | 2016-06-28 | Intercept Pharmaceuticals, Inc. | Tgr5 modulators and methods of use thereof |
US8338628B2 (en) * | 2007-08-28 | 2012-12-25 | City Of Hope | Method of synthesizing alkylated bile acid derivatives |
US8796249B2 (en) | 2008-07-30 | 2014-08-05 | Intercept Pharmaceuticals, Inc. | TGR5 modulators and methods of use thereof |
ES2458168T3 (en) | 2008-11-19 | 2014-04-30 | Intercept Pharmaceuticals, Inc. | TGR5 modulators and their method of use |
US9982008B2 (en) | 2012-06-19 | 2018-05-29 | Intercept Pharmaceuticals, Inc. | Preparation and uses of obeticholic acid |
DK3336097T3 (en) | 2012-06-19 | 2020-09-28 | Intercept Pharmaceuticals Inc | Preparation of non-crystalline obeticholic acid |
CA2912139C (en) * | 2013-05-14 | 2021-04-20 | Roberto Pellicciari | 11-hydroxyl-derivatives of bile acids and amino acid conjugates thereof as farnesoid x receptor modulators |
EA031003B1 (en) | 2013-09-11 | 2018-10-31 | Инсерм (Энститю Насьональ Де Ля Сантэ Э Де Ля Решерш Медикаль) | Methods and pharmaceutical compositions for the treatment of hepatitis b virus infections |
CN104672290B (en) * | 2015-01-05 | 2017-06-06 | 北京普禄德医药科技有限公司 | A kind of medicine of disease for preventing or treating FXR mediations and its production and use |
JP2020508316A (en) | 2017-02-21 | 2020-03-19 | ジェンフィGenfit | Combination of PPAR agonist and FXR agonist |
WO2018178260A1 (en) | 2017-03-30 | 2018-10-04 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for reducing persistence and expression of episomal viruses |
EP3705487B1 (en) * | 2017-11-02 | 2022-10-26 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Method for preparing cholic acid compound |
KR20220035365A (en) | 2019-07-18 | 2022-03-22 | 엔요 파마 | How to reduce the side effects of interferon |
WO2021144330A1 (en) | 2020-01-15 | 2021-07-22 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of fxr agonists for treating an infection by hepatitis d virus |
EP4277622A1 (en) | 2021-01-14 | 2023-11-22 | ENYO Pharma | Synergistic effect of a fxr agonist and ifn for the treatment of hbv infection |
TW202308629A (en) | 2021-04-28 | 2023-03-01 | 法商Enyo製藥公司 | Strong potentiation of tlr3 agonists effects using fxr agonists as a combined treatment |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0312867A1 (en) * | 1987-10-20 | 1989-04-26 | GIULIANI S.p.A. | Billiary acid derivatives, processes for the preparation thereof and phamaceutical compositions containing them |
EP0393493A2 (en) * | 1989-04-17 | 1990-10-24 | GIULIANI S.p.A. | Fluorinated bile acid derivatives, processes for the preparation thereof and pharmaceutical compositions containing them |
WO2002072598A1 (en) * | 2001-03-12 | 2002-09-19 | Roberto Pellicciari | Steroids as agonists for fxr |
-
2002
- 2002-07-12 IT IT2002MI001532A patent/ITMI20021532A1/en unknown
-
2003
- 2003-07-11 WO PCT/EP2003/007512 patent/WO2004007521A2/en not_active Application Discontinuation
- 2003-07-11 AU AU2003250935A patent/AU2003250935A1/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0312867A1 (en) * | 1987-10-20 | 1989-04-26 | GIULIANI S.p.A. | Billiary acid derivatives, processes for the preparation thereof and phamaceutical compositions containing them |
EP0393493A2 (en) * | 1989-04-17 | 1990-10-24 | GIULIANI S.p.A. | Fluorinated bile acid derivatives, processes for the preparation thereof and pharmaceutical compositions containing them |
WO2002072598A1 (en) * | 2001-03-12 | 2002-09-19 | Roberto Pellicciari | Steroids as agonists for fxr |
Non-Patent Citations (1)
Title |
---|
PARKS D J ET AL: "BILE ACIDS: NATURAL LIGANDS FOR AN ORPHAN NUCLEAR RECEPTOR", SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE, NEW YORK, US, vol. 284, May 1999 (1999-05-01), pages 1365 - 1368, XP000892009, ISSN: 0036-8075 * |
Also Published As
Publication number | Publication date |
---|---|
AU2003250935A8 (en) | 2004-02-02 |
WO2004007521A2 (en) | 2004-01-22 |
AU2003250935A1 (en) | 2004-02-02 |
ITMI20021532A1 (en) | 2004-01-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2004007521A3 (en) | Bile acid derivatives as agonists of the farnesoid x receptor | |
BE2017C018I2 (en) | ||
WO2005082925A3 (en) | Novel steroid agonist for fxr | |
AU6966498A (en) | Thiazolidinedione and oxazolidinedione derivatives having antidiabetic, hypol ipidaemic and antihypertensive properties | |
NO20050666L (en) | 2,7-substituted indoles and their use as 5-HT6 modulators | |
MXPA02012033A (en) | 2-aminocarbonyl-9h-purine derivatives. | |
WO2003084936A8 (en) | Amino substituted pyrimidinone derivatives useful in the treatment of inflammation and immunological | |
WO2003082205A3 (en) | Compounds and methods | |
WO2002010154A3 (en) | Substituted heterocyclic amides | |
WO2003082192A3 (en) | Certain pharmaceutically useful substituted aminoalkyl heterocycles | |
WO2003066594A3 (en) | 3-alkanoylamino-propionic acid derivatives used as inhibitors of integrin avss6 | |
MXPA05009282A (en) | Substituted aniline derivatives. | |
AU1572301A (en) | Cyclopentyl sulfonamide derivatives | |
MXPA05006889A (en) | Aromatic compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents. | |
AU2003226765A1 (en) | Azaindolylpiperidine derivatives as antihistaminic and antiallergic agents | |
WO2005100322A8 (en) | Sulphur-linked imidazole compounds for the treament of hiv | |
EP1434762A4 (en) | 4'-methanesulfonyl-biphenyl derivatives as a highly selective cyclooxygenase-2 inhibitor | |
BR0207886A (en) | Cyclopropaheterocycles as non-nucleoside reverse transcriptase inhibitors | |
WO2003093247A3 (en) | Antibacterial agents | |
WO2004048381A3 (en) | Pyrazoloazepine compounds as pharmaceutical agents | |
SG171472A1 (en) | Substituted aniline derivatives | |
AU7109798A (en) | Substituted thiazolidinedione and oxazolidinedione having antidiabetic, hypol ipidemia and antihypertensive properties | |
MXPA05006587A (en) | Thiazole compounds as integrin receptor antagonists derivatives. | |
WO2004093796A3 (en) | Lactam derivatives and methods of their use | |
WO2004054983A3 (en) | 1-n-phenylamino-1h-imidazole derivatives as aromatase inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: JP |